Staff

Novo Nordisk and Omeros announce asset purchase and license agreement for Omeros’ clinical-stage MASP-3 inhibitor zaltenibart (OMS906)

Zaltenibart has best-in-class potential across multiple rare blood and kidney disorders and will enhance Novo Nordisk’s Rare Disease portfolioOmeros is...

Safex Chemicals India Ltd. Receives Frost & Sullivan’s 2025 Global Competitive Strategy Leadership Recognition for Excellence in Crop Protection Chemicals

Safex earns global recognition for its innovation-driven strategy, digital transformation, and customer-centric approach in the evolving crop protection chemicals industry....

DOCREPLAY.ai Unveils WHY+: Breakthrough Hybrid AI Platform Redefines Voice Technology and Sets a Higher Industry Standard for Qualitative Research at Scale

Purpose-built AI platform integrates intelligent agent technology with proprietary voice capture to deliver practical healthcare intelligence at scale while eliminating...

error: Content is protected !!